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Abstract
Background: Human brain aging has received special attention in part because of the elevated risks of neurodegenerative
disorders such as Alzheimer’s disease in seniors. Recent technological advances enable us to investigate whether similar
mechanisms underlie aging and neurodegeneration, by quantifying the similarities and differences in their genome-wide
gene expression profiles.
Principal Findings: We have developed a computational method for assessing an individual’s ‘‘physiological brain age’’ by
comparing global mRNA expression datasets across a range of normal human brain samples. Application of this method to
brains samples from select regions in two diseases – Alzheimer’s disease (AD, superior frontal gyrus), frontotemporal lobar
degeneration (FTLD, in rostral aspect of frontal cortex ,BA10) – showed that while control cohorts exhibited no significant
difference between physiological and chronological ages, FTLD and AD exhibited prematurely aged expression profiles.
Conclusions: This study establishes a quantitative scale for measuring premature aging in neurodegenerative disease
cohorts, and it identifies specific physiological mechanisms common to aging and some forms of neurodegeneration. In
addition, accelerated expression profiles associated with AD and FTLD suggest some common mechanisms underlying the
risk of developing these diseases.
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Introduction
Human brain aging and neurodegenerative diseases
Among human tissues, the brain in normal aging and in
neurodegenerative disease has received special attention. This
interest stems largely from the observation that as humans age
most develop some degree of cognitive decline. While slight,
differences in performance in tasks of visual and verbal memory
[1,2], abstraction [3], and naming and verbal fluency [4] exist
between aged individuals and their younger counterparts.
Moreover, measurable differences in cognitive performance are
seen in both cross-sectional and longitudinal-design studies [5]. In
daily life, these differences are too small and too common to be
considered pathological. In some aging individuals, however,
pathological decline in cognitive function in the form of a
dementing neurodegenerative illness does develop.
Alzheimer’s disease (AD) is the most well known of these
dementing neurodegenerative diseases. Affecting at least 4.5
million Americans [6], AD causes decline in memory as well as
other aspects of cognition [7]. Although less common, another
neurodegenerative cause of dementia is frontotemporal lobar
degeneration (FTLD). Clinically, patients with FTLD exhibit
progressive decline in behavior, executive function (e.g. ability to
make decisions), and language.
In the case of AD, specific genes and proteins have been
implicated in pathogenesis (reviewed in [8,9]). For example,
important genetic risk factors for AD include APOE genotype,
while rare mutations in PS1, PS2, and APP can cause primarily
familial forms of disease [10]. In addition, specific proteins (beta-
amyloid, tau) certainly play a role in disease pathogenesis,
aggregating in different forms in diseased vs. normal tissue
[11,12]. While substantial evidence implicates these genes and
proteins in AD pathogenesis, their precise functions in the
pathological cascade that leads to AD is still a subject of
considerable debate.
Regarding FTLD, a substantial proportion (precise number?) of
cases are attributable to mutations in either the gene for
progranulin (GRN), which cause disease through a haploinsuffi-
ciency mechanism (reviewed in [13]) or the MAPT gene [14].
Other cases of FTLD remain enigmatic, but, as in AD, the
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43kD TAR DNA-binding protein (TDP-43, [15]), appears to play
a role (reviewed in [16,17,18,19]). For both diseases, the clinical
course is progressive and ultimately fatal, and neuropathological
examination reveals extensive neurodegeneration. While the core
area of neurodegeneration differs among the diseases (hippocam-
pal formation in AD, frontal and temporal lobes in FTLD), both
diseases affect the frontal cortex.
The risk of developing a neurodegenerative disease increases
with age. For example, in one US study, the estimated annual
incidence of Alzheimer’s Disease (AD) increased from 0.6% in
individuals aged 65–69 years, to 2% in those aged 75–80 years, to
8.4% in those aged 85 years and older [6]. Not all neurodegen-
erative diseases occur with greater frequency as individuals age,
however. In FTLD, for instance, prevalence may be higher in
individuals aged 60–69 years than in those aged 70–79 years [20].
When evaluated worldwide without reference to cause, however,
rates of dementia consistently increase with age despite variability
between regions of the world and between developed and
developing countries [21].
These findings beg the question of whether ‘‘normal’’ and
‘‘pathological’’ cognitive decline are really on a spectrum, with
one’s position on that spectrum shifting with age. Put another way,
one might ask whether there are underlying processes in common
between aging and neurodegenerative disease. Common mecha-
nisms in aging and neurodegeneration certainly seem plausible.
Indeed, mechanisms such as mitochondrial dysfunction and DNA
damage have been implicated in both aging and neurodegener-
ation (reviewed in [22]). More generally, aging has long been
understood to be accompanied by cumulative insults to cells that
eventually lead to their degeneration and demise.
Profiling gene expression in aging and
neurodegenerative diseases
With the advent of technology allowing for genome-wide
surveys of gene expression, studies of aging have become feasible
at the molecular level. Using gene expression microarrays, genes
associated with the aging process have been identified [23,24,25].
Moreover, these genes have been used as age biomarkers to
establish the physiological age of organisms [26,27], detect tissue-
specific aging differences [24,28,29,30] and study the biology of
aging-related diseases [31,32].
These advances also make it possible to address the question of
whether aging and neurodegeneration are mechanistically similar
in a novel way. Clinical and pathological descriptors are fairly
downstream phenotypes for a process, be it neurodegeneration or
aging. In contrast, global mRNA expression profiles are very
upstream phenotypes that hint at specific biological mechanisms.
Indeed, we and others have shown that extensive transcriptional
changes occur in brain tissue from patients with AD [31,33], and
FTLD [16,34], with specific molecular pathways implicated in
both diseases (reviewed in [16]). Although these microarray studies
have attempted to control for the effect of age on gene expression,
a question that remains unanswered (and largely unasked) is that of
how similar the transcriptional changes that occur with aging are
to the transcriptional changes that occur with specific neurode-
generative diseases.
Outline of the paper
In this study, we developed a method using global gene
expression data to accurately determine the age of a normal brain
sample. We then employed this method to ask whether samples
from patients with neurodegenerative diseases look ‘‘older’’ at a
molecular level than their age-matched non-diseased counterparts.
We examined neurodegenerative diseases that increase in
incidence with age (e.g. AD), and those in which the relationship
between age and disease incidence is unclear (e.g. FTLD). We
found that both neurodegenerative diseases, in specific regions of
the brain, show characteristics of accelerated aging.
Results
Age prediction using brain gene expression
We used three reference datasets of gene expression in normal
human brain to train and test our age predictor using datasets
D1,D3 in Table 1. As described in the Methods section, error in
age prediction was estimated using data from 80% of the subjects
to predict ages in the remaining 20%. We found that age
prediction by global gene expression was accurate within 10.5 to
16 years of the actual age of the subject, with variation in the
error depending on the brain region used (Table 2). When we
randomly permuted the ages of the individuals in each brain
dataset (1000 permutations performed), no more than 0.5% of
the permutations had age prediction errors that were less than
our observed error of 10.5,16 years. We also found that the
difference of actual and predicted median age on the same group
of subjects (between 5 and 6 subjects in the 20% partition) by
cross validation is between 5.41 and 8.83 years. The decrease in
error is proportional with the square root of sample size minus 1
and is similar to the behavior of standard deviation as one moves
from estimating individuals to estimating population behavior.
We estimate the error will be between 2.24 and 3.41 years when
estimating the median age of 23 AD samples. Therefore, our age
predictor performed significantly better than would be expected
by random chance, and can be used to study the population
accurately.
Region-specific correlations between age and gene
expression levels in human frontal cortex
As described in the Methods section, we tested our age predictor
using three independent normal human brain datasets. These
profiled gene expression in three different areas of the frontal
cortex: the rostral part of the frontal cortex (roughly BA10, D1)
[24], dorsolateral prefrontal cortex (BA9, D2), and orbital
prefrontal cortex (BA47, D3) [28] (Figure 1). Subjects in each
dataset were between 20 and 95 years old, with individuals in
every decade. We ran linear regressions on the three datasets and
applied a nominal p value cut-off at 0.01 to obtain three age-
correlated gene lists. We examined the overlaps among the three
datasets (D1,D3), and found that the identities of the age-
correlated genes in the three regions were very different (Figure 2).
Out of over 810 genes with age-correlated gene expression in at
least one Brodmann Area, only 40 genes showed age-correlated
gene expression in both BA9 and BA47, and only 39 genes showed
age-correlated gene expression in both BA9 and BA10. BA47 and
BA10 had the least overlap, with only 15 genes showing age-
correlated gene expression in both areas.
For each of the three datasets, we analyzed the biological
significance of the age-correlated genes using Gene Set Enrich-
ment Analysis (GSEA) [35]. We focused on Category 5 (Gene
Ontology, GO) and analyzed genes positively correlated with
aging (i.e. greater age=greater expression) and genes negatively
correlated with aging (i.e. lesser age=greater expression) separate-
ly. As shown in Table S1, we found that age-correlated genes in
dataset D2 (BA9) were functionally more similar to D3 (BA47). Of
note, many genes negatively correlated with age appeared to be
involved in mitochondrial function.
Gene Expression of Brain Aging
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disorders
Having demonstrated that estimation of chronological age using
global brain gene expression is possible in normal individuals, we
next turned our attention to samples from individuals with
neurodegenerative diseases. We examined two different neurode-
generative diseases: AD, a disease highly associated with aging;
and FTLD, a disease possibly associated with aging. For the
analysis of microarray datasets pertaining to these two neurode-
generative disorders, we matched the brain region of reference
data (used to build the predictor) and target data (control and
patient gene expression profiles) (Figure 1). We did this because of
the regional differences in age-correlated gene expression
described in the previous section. See Table 1 for pairing of
reference and target datasets.
Applying our age predictor to AD, we found that brain samples
from AD patients had an ‘‘older’’ expression profile than control
samples of the same chronological age. The median chronological
age for the AD patients (23 individuals between 68 and 90 years,
D5 in Table 1) was 79 years. However, by global gene expression
trained on region-matched normal controls (D2 in Table 1), the
median predicted age for the AD cohort was 83.89 years. In
contrast, neurologically normal control samples from the same
microarray study (11 individuals between 63 and 102 years, D5 in
Table 1) showed minimal differences in median chronological age
(79 years) and age as predicted by gene expression (78.55 years).
The difference between chronological and predicted ages in AD
was highly significant (p=0.0002), whereas the difference in
chronological and predicted ages in normal controls was not
(p=0.97) (Figure 3). Taken together, these data indicate that AD
superior frontal gyrus samples show a prematurely aged global
gene expression profile. Global gene expression trained on BA10
(D1 in Table 1) and similar prediction on AD patients also led to
the same conclusion (Figure S1).
Having seen an ‘‘older’’ expression profile in AD brains
compared to normal controls, we next evaluated FTLD, one of
the most common causes of dementia after AD. Specifically, we
considered the form of FTLD with underlying TDP-43 pathology
(FTLD-TDP), which is the most common neuropathological
substrate of the clinical entity FTLD [18,36]. A significant
proportion of FTLD-TDP is caused by mutations in the GRN
gene [13], and we have previously demonstrated that FTLD-TDP
with GRN mutations has a frontal cortex gene expression profile
distinct from FTLD-TDP without GRN mutations [16]. We
therefore analyzed the two subgroups of FTLD-TDP, cases with
and without GRN mutations, separately. As with AD, we matched
brain regions used in our training set and test set (D1 and D4,
respectively, in Table 1) and normalized across datasets using the
expression of housekeeping genes.
Despite small sample sizes (6 FTLD-TDP patients with GRN
mutations, 10 FTLD-TDP patients without GRN mutations), we
found that both subgroups had a significantly ‘‘older’’ gene
expression profile than neurologically normal controls of the same
chronological age. Specifically, FTLD-TDP patients with GRN
mutations had a median chronological age of 73.5 years but a
median predicted age of 102.18 years as estimated by frontal
cortex global gene expression (p=0.031). FTLD-TDP patients
without GRN mutations had similarly ‘‘aged’’ brain gene
expression, with a median chronological age of 63.5 years but a
median predicted age of 84.12 years (p=0.002). In contrast,
neurologically normal controls from the same dataset (8
individuals ranging from 47 to 92 years of age, D4 in Table 1)
had a median chronological age (72 years) that was not
significantly different from median predicted age (66.77 years,
Table 1. Microarray data sets used in this paper and corresponding human brain regions.
Brain regions Normal FTLD AD
Rostral aspect of frontal D1: 29 [24] D4: [16]* D5: [33]
cortex (,BA10) Age: 26,95; F: 11; M: 18 GRN+: 6 AD : 23
GEO#: GDS707 Age: 62,79; F: 3; M: 3 Age: 68,90; F: 10; M: 13
GRN2: 10 Ctrl: 11
Age: 48,77; F: 6; M: 4 Age: 63,102; F: 4; M: 7
Ctrl: 8 GEO#: GSE5281
Age: 47,92; F: 3; M: 5 (Superior frontal gyrus covers
GEO#: GSE13162 both BA9 and BA10)
Dorsolateral prefrontal D2: 29 [28]*
cortex (BA9) Age: 25,79; F: 7; M: 22
BA47 D3: 27 [28]*
Age: 28,77; F: 6; M: 21
*obtained from the authors directly.
doi:10.1371/journal.pone.0013098.t001
Table 2. Significance of the error by obtaining 1,000
randomized cross-validation errors with age information
randomly shuffled; the significance of the prediction error is
the fraction of the 1,000 randomized errors lower than the
actual cross-validation error.
D1 (BA10) D2 (BA9) D3 (BA47)
Error in age prediction 16.0967.69 11.1565.62 10.4966.92
(five-fold cross validation)
Difference of median of age 7.92 8.83 5.41
(with actual age)
Median of difference of age 6.86 8.20 6.21
(with actual age)
Permutation test P values 0 0.005 0.002
doi:10.1371/journal.pone.0013098.t002
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TDP and AD brain appears markedly ‘‘older’’ than the actual
chronological age of patient samples.
Overlap between age-correlated genes and differentially
expressed genes in neurodegenerative disorders
W en e x te v a l u a t e dt h eo v e r l a po fa g i n g - c o r r e l a t e dg e n e s
(nominal p,0.005) and AD- or FTLD-TDP-associated genes,
(nominal p,0.001) in the same or similar regions of the brain
(Table S2). As would be predicted by our findings of a
‘‘prematurely aged’’ gene expression profile in AD, we found
a statistically significant overlap of age-correlated genes and
AD-associated genes (p=3.34610
24 by Fisher’s exact test).
Similarly, in FTLD-TDP, where we also found a ‘‘prematurely
aged’’ gene expression profile, we observed a statistically
significant overlap of age-correlated genes and FTLD-TDP-
associated genes in both FTLD-TDP patients with GRN
mutations (p=2.02610
26 by Fisher’s exact test) and FTLD-
TDP patients without GRN mutations (p=1.21610
24 by
Fisher’s exact test).
Towards the discovery of common mechanisms in aging
and FTLD
Our finding of prematurely aged gene expression in FTLD-
TDP and AD implies that aging and these neurodegenerative
diseases have mechanisms in common and leads to the question of
what these common mechanisms might be.
Having demonstrated in the previous section that a significant
overlap exists between genes associated with aging and with
FTLD-TDP, we evaluated the identity of those genes showing
differential expression in both aging and FTLD-TDP. The
rationale for doing so was to find genes and pathways shared
between physiologic aging and pathophysiologic mechanisms in
FTLD-TDP. Because of the large number of genes with altered
expression in FTLD-TDP, we used relatively stringent statistical
(p,0.001) and fold-change (FC.2) cut-offs to identify genes
robustly associated with disease [16]. 17 genes (Table S3) showed
differential expression in both aging and FTLD-TDP. For 16 of
these genes, the direction of age-associated gene expression (e.g.
Figure 1. Microarray data sets used in this paper and corresponding human brain regions. Regions and abbreviations: SFG, superior
frontal gyrus; BA10, rostral aspect of frontal cortex; BA9, dorsolateral prefrontal cortex; and BA47, orbital prefrontal cortex. See Table 1 for detailed
information of correspondence between brain regions and data sets used in this study. The brain illustration is downloaded from wikipedia.org, a
reproduction based on the 1918 edition Gray’s Anatomy. The image is in the public domain; see Licensing on http://en.wikipedia.org/wiki/
File:Gray728.svg.
doi:10.1371/journal.pone.0013098.g001
Figure 2. Venn diagram of three human brain regions. Age-
correlated genes (p#0.01) in three human brain regions are very
different. Shown are the numbers of genes with age-correlated
expression in each brain region.
doi:10.1371/journal.pone.0013098.g002
Gene Expression of Brain Aging
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direction of FTLD-TDP-associated gene expression (e.g. higher in
FTLD-TDP patients vs. controls) (Table S3).
Among these genes, HSPA2 encodes a heat-shock protein of the
70kD family, which operates as a molecular chaperone in response
to cellular stress. LAMP2 encodes a protein that functions
specifically in the maintenance of lysosomes and more generally
in the regulation of autophagy. Autophagy (reviewed in [37,38])
and heat-shock proteins (reviewed in [39]) have been implicated in
both aging and neurodegeneration, corroborating our general
result that some neurodegenerative diseases have mechanisms in
common with aging.
Discussion
In this paper, we developed a computational method for
assessing an individual’s ‘‘physiological brain age’’ based on global
mRNA expression. We applied our method to five human brain
microarray datasets and found that global gene expression can be
used to predict the chronological age of a normal brain sample.
Figure 3. Comparison between actual and predicted ages of controls and AD patients. We compared observed and predicted ages for
controls and AD patients. While the difference between observed and predicted age was not significant for controls, AD patient samples had a
significantly older predicted age compared to the actual observed age. (Top) Numbers of subjects, medians of ages, and P-values for Wilcoxon test
are shown. (Bottom) Box and whiskers plots of observed and predicted ages for controls and AD patients. Box represents median (bar) and
interquartile range, while whiskers represent range of all values excepting outliers (shown as open circles). Reference data set used for training our
age predictor was D2 (BA9), and genes used for age prediction were selected using a nominal p-value cut-off of 0.005.
doi:10.1371/journal.pone.0013098.g003
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PLoS ONE | www.plosone.org 5 September 2010 | Volume 5 | Issue 9 | e13098We further found that age-correlated gene expression differs
among different regions of brain. Finally, we applied our age-
prediction method to demonstrate that the neurodegenerative
diseases FTLD-TDP and AD exhibit prematurely aged gene
expression profiles in specific brain regions.
Among normal samples, our model was able to predict the
chronological age of a sample within approximately 11 years in
two datasets (D2 and D3). Others have found a similar degree of
error using global gene expression to predict age [28] in datasets
obtained under the same experimental conditions on the same
microarray platforms. Our methodology therefore allows for a
comparable degree of accuracy in age prediction under the much
noisier conditions introduced by independently obtained datasets.
This advantage is important when considering applications of
cross-dataset analyses.
It is worth noting here that the difference in age predicted by
global gene expression and chronological age for a given sample
may not simply be due to error in prediction methodology. That
is, an individual’s physiological age – defined as that age most
accurately representing the sum of insults to cells, tissues, and
organs that make up the individual – may not coincide exactly
with his or her chronological age. One would expect gene
Figure 4. Comparison between actual and predicted ages of controls and FTLD-TDP patients. We compared observed and predicted
ages for controls and FTLD-TDP patients with (GRN+) and without (GRN2) GRN mutations. While the difference between observed and predicted age
was not significant for controls, FTLD-TDP patient samples had significantly older predicted ages compared to actual observed ages, regardless of
GRN mutation status. (Top) Numbers of subjects, medians of ages, and P-values for Wilcoxon test are shown. (Bottom) Box and whiskers plots of
observed and predicted ages for controls and FTLD-TDP patients. Box represents median (bar) and interquartile range, while whiskers represent
range of all values excepting outliers (shown as open circles). Reference data set used for training our age predictor was D1 (BA10), and genes used
for age prediction were selected using a nominal p-value cut-off of 0.005.
doi:10.1371/journal.pone.0013098.g004
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PLoS ONE | www.plosone.org 6 September 2010 | Volume 5 | Issue 9 | e13098expression profiles to reflect this concept of physiological age and,
as such, to only approximate the chronological age even in the
case of a perfect method. This point was elegantly illustrated in a
recent study of global gene expression at different time points
across the lifespan of the nematode worm [40], where behavioral
phenotypes were used as proxies for physiological age in addition
to straightforward comparison with chronological age.
Our finding that different regions of human brain exhibit
different patterns of age-correlated gene expression corroborates
work by others [41] demonstrating prominent differences in age-
related gene expression between samples from the superior frontal
gyrus and precentral gyrus. Such a finding is not surprising given
the different connections and functions of even neighboring brain
regions, but it does mean that attention must be paid to regional
differences when interpreting mRNA expression profiling data.
Using our age prediction method, we showed that AD and
FTLD-TDP patient brains exhibit prematurely aged gene
expression profiles. Such a finding supports the intuitive notion
that aging and at least these two neurodegenerative diseases have
mechanisms in common. Although not surprising, our finding is
nonetheless important for several reasons. First, we have
established in a quantitative way on a common scale the degree
to which various neurodegenerative diseases resemble aging (e.g.
AD ‘‘adds 5 years’’ to a brain sample). Second, we can identify
specific physiologic/pathophysiologic mechanisms common to
both aging and various neurodegenerative diseases. An example
of such an application is the identification of autophagy and heat-
shock response genes with altered expression in both aging and
FTLD-TDP. The fact that a substantial body of literature already
exists linking these two biological pathways to both aging and
neurodegeneration lends validity to our approach; other genes and
pathways identified in a similar manner may provide avenues for
future research.
We considered the possibility that our finding of a ‘‘prematurely
aged’’ global gene expression signature is simply an artifact of
neuronal loss. While we cannot completely exclude this possibility,
the fact that we observe such different age-correlated genes in
adjacent areas of frontal cortex (which are similarly affected in
terms of neuronal loss) argues that our findings are unlikely to be
due to neuronal loss alone.
Our finding of prematurely aged gene expression in FTLD-
TDP and AD suggests the possible commonalities between aging
and these neurodegenerative diseases, and supports the notion that
transcriptome profiling can be an informative approach for
investigating these commonalities, when larger datasets for normal
brain aging become available. It remains to be shown how much
the overlap corresponds to any common mechanism between
normal aging and neurodegenerative disorders or common
responses without etiological implications. However, recent
advances in expression quantitative trait linkage (eQTL)
[42,43,44] may eventually provide a causal link connecting some
susceptible loci and changes in gene expression.
Materials and Methods
Data preparation
Microarray datasets used in this paper were either generated by
us as previously described (Chen-Plotkin et al. 2008), downloaded
from GEO (http://www.ncbi.nlm.nih.gov/geo/index.cgi), or ob-
tained from the authors directly. Table 1 summarizes the data
used in this paper. For all datasets, the GCRMA package [45] for
R/Bioconductor [46] was used to generate log-2 expression levels
for probeset IDs from the original .cel files. Ages for healthy
individuals used in this study ranged from 20 to 95 years. For the
purposes of this study, individuals with psychiatric diagnoses from
one dataset [28] were classified with normal controls, as they had
previously been shown not to differ in age-related gene expression
from individuals without psychiatric diagnoses.
Predicting age using microarray experiments
We used linear regression to compute the significance of a
correlation between age and the expression level of a gene,
adjusting for the effect of gender. This approach assumes a linear
relationship between age and log-2 expression level:
Yij~mizb1iAjzb2iSjzb3iAMale
j zeij ð1Þ
Here Yij is the log-2 gene expression level of probe set i in sample j,
Aj is the age for individual j, Sj is 0 if individual j is female, 1 if he is
male. Aj
Male is the age of individual j if Sj=1; it is 0 otherwise
(included to test for interaction between age and gender). The
coefficients b1i, b2i, and b3i are regression coefficients reflecting the
rate of change in gene expression with respect to age alone, gender
alone, and age-gender interaction effects, respectively.
The model was computed on normal individuals in different
brain regions (Table 1). To minimize the interaction of gender in
age prediction, we filtered out any genes that have p$0.05 for b2i
and b3i. Then genes significantly correlated with age (p#0.005 for
b1i were used in the predictor to estimate the physiological age of
control subjects and subjects with neurodegenerative disease in the
corresponding brain regions D1, D2, D3. We used five-fold cross
validation to estimate the error of our age predictor; see
Supplemental Methods S1 for more details.
In order to apply our age predictor across diverse microarray
experiments, we needed to address two issues: microarray platform
differences and baseline differences attributable to variations in
experimental technique. To address the former, we used the best-
match probeset ID tables provided by Affymetrix (https://www.
affymetrix.com/support/technical/comparison_spreadsheets.affx)
to match probeset IDs on different human genome microarrays
used in this paper. For the latter, we assumed that the difference
between two microarray experiments is a constant offset. We
adjusted this baseline difference by estimating the difference
between the expression levels of housekeeping genes common to
the two datasets. 575 established housekeeping genes [47] were
used in this calibration. We found that the difference between
median predicted age and median actual age were 3.01 years and
2.99 years, and none were significant by Wilcoxon’s test (Figure
S2). This suggests that experimental baseline differences between
microarray studies can be ignored. See Supplemental Methods S1
for details and validation of the calibration procedure.
Application of age-predictor to disease datasets
For each neurodegenerative disease studied, we trained our age
predictor on a reference dataset assaying gene expression in
normal controls from the same brain region used in the target
dataset (microarray dataset consisting of diseased individuals and
their neurologically normal controls). We then applied the age
predictor to two different test sets: the normal controls within the
target dataset and the diseased individuals within the target
dataset. We calculated the median predicted age for each test set
and compared it to the median chronological age for the same test
set. We then evaluated the significance of the difference between
predicted ages and chronological ages in the test set using a paired
Wilcoxon test. We examined the overlap between differentially
expressed genes in neurodegenerative disorders age-correlated
genes in region-matched normal brain aging. The significance of
Gene Expression of Brain Aging
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both differentially expressed in neurodegenerative diseases (AD,
FTLD-TDP) and correlated with age can be found in Table S3,
Table S4 and Table S5.
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